Photo Credit: Mst Hazera Begum
Moderators: William Gradishar, Northwestern University Feinberg School of Medicine, Chicago, Illinois, and Sara Hurvitz, Fred Hutchinson Cancer Center, Seattle, Washington
Case Presentations and Discussants:
Michael Oliphant, Harvard Medical School, Boston, Massachusetts
Marla Lipsyc-Sharf, UCLA Health, Santa Monica, California
Neil Vasan, Columbia University Irving Medical Center, New York, New York
Dan Stover, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Amy Beumer, Patient Advocate, Mason, Ohio
- Case 1: New diagnosis ER+HER2-MBC: genomic considerations
- Case 2: Can we delay CDK4/6i treatment until the second line?
- Case 3: Selecting therapy after progression of disease on CDK4/6i therapy in patients with PI3K pathway mutations
- Case 4: Selecting treatment for patient with tumor ESR1 mutation
- Case 5: When it’s time to move on from endocrine approaches, chemo or ADC?
